Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T97637
|
|||||
| Target Name |
Glutathione S-transferase LANCL1 (LANCL1)
|
|||||
| Synonyms |
p40; LanC-like protein 1; GPR69A; 40 kDa erythrocyte membrane protein
Click to Show/Hide
|
|||||
| Gene Name |
LANCL1
|
|||||
| Target Type |
Literature-reported target
|
[1] | ||||
| Function |
Functions as glutathione transferase. Catalyzes conjugation of the glutathione (GSH) to artificial substrates 1-chloro-2,4-dinitrobenzene (CDNB) and p-nitrophenyl acetate. Mitigates neuronal oxidative stress during normal postnatal development and in response to oxidative stresses probably through GSH antioxidant defense mechanism (By similarity). May play a role in EPS8 signaling. Binds glutathione.
Click to Show/Hide
|
|||||
| UniProt ID | ||||||
| EC Number |
EC 2.5.1.18
|
|||||
| Sequence |
MAQRAFPNPYADYNKSLAEGYFDAAGRLTPEFSQRLTNKIRELLQQMERGLKSADPRDGT
GYTGWAGIAVLYLHLYDVFGDPAYLQLAHGYVKQSLNCLTKRSITFLCGDAGPLAVAAVL YHKMNNEKQAEDCITRLIHLNKIDPHAPNEMLYGRIGYIYALLFVNKNFGVEKIPQSHIQ QICETILTSGENLARKRNFTAKSPLMYEWYQEYYVGAAHGLAGIYYYLMQPSLQVSQGKL HSLVKPSVDYVCQLKFPSGNYPPCIGDNRDLLVHWCHGAPGVIYMLIQAYKVFREEKYLC DAYQCADVIWQYGLLKKGYGLCHGSAGNAYAFLTLYNLTQDMKYLYRACKFAEWCLEYGE HGCRTPDTPFSLFEGMAGTIYFLADLLVPTKARFPAFEL Click to Show/Hide
|
|||||
| 3D Structure | Click to Show 3D Structure of This Target | PDB | ||||
| Cell-based Target Expression Variations | Top | |||||
|---|---|---|---|---|---|---|
| Cell-based Target Expression Variations | ||||||
| Drug Binding Sites of Target | Top | |||||
|---|---|---|---|---|---|---|
| Ligand Name: Glutathione | Ligand Info | |||||
| Structure Description | Crystal Structure of Human LanCL1 complexed with GSH | PDB:3E73 | ||||
| Method | X-ray diffraction | Resolution | 2.80 Å | Mutation | No | [2] |
| PDB Sequence |
SMDIEFMAQR
4 AFPNPYADYN14 KSLAEGYFDA24 AGRLTPEFSQ34 RLTNKIRELL44 QQMERGLKSA 54 DPRDGTGYTG64 WAGIAVLYLH74 LYDVFGDPAY84 LQLAHGYVKQ94 SLNCLTKRSI 104 TFLCGDAGPL114 AVAAVLYHKM124 NNEKQAEDCI134 TRLIHLNKID144 PHAPNEMLYG 154 RIGYIYALLF164 VNKNFGVEKI174 PQSHIQQICE184 TILTSGENLA194 RKRNFTAKSP 204 LMYEWYQEYY214 VGAAHGLAGI224 YYYLMQPSLQ234 VSQGKLHSLV244 KPSVDYVCQL 254 KFPSGNYPPC264 IGDNRDLLVH274 WCHGAPGVIY284 MLIQAYKVFR294 EEKYLCDAYQ 304 CADVIWQYGL314 LKKGYGLCHG324 SAGNAYAFLT334 LYNLTQDMKY344 LYRACKFAEW 354 CLEYGEHGCR364 TPDTPFSLFE374 GMAGTIYFLA384 DLLVPTKARF394 PAFEL |
|||||
|
|
||||||
| Click to View More Binding Site Information of This Target with Different Ligands | ||||||
| Different Human System Profiles of Target | Top |
|---|---|
|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Tissue Distribution
of target is determined from a proteomics study that quantified more than 12,000 genes across 32 normal human tissues. Tissue Specificity (TS) score was used to define the enrichment of target across tissues.
The distribution of targets among different tissues or organs need to be taken into consideration when assessing the target druggability, as it is generally accepted that the wider the target distribution, the greater the concern over potential adverse effects
(Nat Rev Drug Discov, 20: 64-81, 2021).
Human Pathway Affiliation
of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function.
Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes
(Pharmacol Rev, 58: 259-279, 2006).
Human Similarity Proteins
Human Tissue Distribution
Human Pathway Affiliation
|
|
|
There is no similarity protein (E value < 0.005) for this target
|
|
Note:
If a protein has TS (tissue specficity) scores at least in one tissue >= 2.5, this protein is called tissue-enriched (including tissue-enriched-but-not-specific and tissue-specific). In the plots, the vertical lines are at thresholds 2.5 and 4.
|
| KEGG Pathway | Pathway ID | Affiliated Target | Pathway Map |
|---|---|---|---|
| Glutathione metabolism | hsa00480 | Affiliated Target |
|
| Class: Metabolism => Metabolism of other amino acids | Pathway Hierarchy | ||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Lanthionine synthetase component C-like protein 2: a new drug target for inflammatory diseases and diabetes. Curr Drug Targets. 2014 Jun;15(6):565-72. | |||||
| REF 2 | Structure of human lanthionine synthetase C-like protein 1 and its interaction with Eps8 and glutathione. Genes Dev. 2009 Jun 15;23(12):1387-92. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.